Trial Profile

A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Cisplatin; Ropidoxuridine
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms REACH

Most Recent Events

03 Nov 2020 Status changed from recruiting to active, no longer recruiting.
24 Oct 2020 Results (n=41) of safety phase with particular focus on skin toxicity published in the European Journal of Cancer
22 Sep 2019 According to a Merck KGaA media release, data from the study will be presented at the 2019 European Society for Medical Oncology (ESMO) Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com